about us


We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, a potential best-in-class HDAC inhibitor, ME-401, a highly selective PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor.

[ Read more ]

latest news

MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A Next-Generation Oral PI3K Delta Inhibitor
[ April 20, 2016 ] [ Poster ]

MEI Pharma Presents at Needham Healthcare Conference
[ Webcast ]

MEI Pharma Appoints Dr. Christine White as Chairman of the Board
[ December 10, 2015 ]

MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in AML, Plans to Initiate Phase III Registration Study
[ December 7, 2015 ]
[ AML Presentation ] [ MDS Presentation ]

Annual Review Cover
Click here for our 2015 Annual Review